8th Canadian Conference on Ovarian Cancer Research 2016 May 15-17 Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Friday, May 20, 2016

8th Canadian Conference on Ovarian Cancer Research 2016 May 15-17



Detailed Programme
 

Detailed Programme 2016


  • Saturday / Sunday, May 15, 2016
  • Monday, May 16, 2016
  • Tuesday, May 17, 2016

Book of Abstracts (.pdf)


Saturday, May 14, 2016


08:00 - 17:30 Registration Open
18:00 - 21:00 Opening Reception in MYST Lounge (Hilton Fallsview)

Sunday, May 15, 2016


07:30 - 08:30 Continental Breakfast in Ballroom Foyer
07:30 - 08:30 Poster Set-up for all Poster Presenters
08:00 - 18:00 Registration Open

08:30 - 10:45  Symposium I - Genetics & Genome Dynamics: Beyond TCGA
Moderators:

Patricia Tonin, PhD, McGill University, Montreal, QC, Canada
Mark Carey, MD, University of British Columbia, Vancouver, BC, Canada

08:30 Welcome Remarks
SY-01.00
Trevor Shepherd, PhD, The University of Western Ontario, London, ON, Canada
Elisabeth Baugh, CEO, Ovarian Cancer Canada, Toronto, ON, Canada
08:45 Determinants of resistance and response in high grade serous ovarian cancer
SY-01.01
David Bowtell
Peter MacCallum Cancer Centre, Melbourne, Australia
09:45 Toward precision medicine for rare and common ovarian cancers
SY-01.02
Douglas Levine
Memorial Sloan Kettering Cancer Center, New York, NY, United States

10:15 - 10:30  Health Break in Ballroom Foyer

10:30 - 12:00  Symposium I (cont.) - Origins of Ovarian Cancer: From Basic Insights to New Screening Strategies

10:30 Clonal evolution in high grade serous ovarian cancer: implications for intraperitoneal spread
SY-01.03
Sohrab Shah
University of British Columbia, Vancouver, BC, Canada
11:00 Probing the genetic architecture of the response to PARP inhibitors
SY-01.04
Daniel Durocher
The Senior Investigator & Assistant Director for Biomedical Research The Lunenfeld-Tanenbaum Research, Toronto, ON, Canada
11:30 Genomic Analysis of Mucinous Tumors (GAMuT): an international study to characterize this rare ovarian subtype
SY-01.05
Kylie Gorringe1; Dane Cheasley1; Matthew Wakefield2; Andrew Stephens3; Scott Kaufmann4; Charlie Gourley5; David Bowtell6; Yoland Antill7; Jessica McAlpine8; Clare Scott9; Ian Campbell1
1Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; 2Walter and Eliza Hall Institute and The University of Melbourne, Parkville, VIC, Australia; 3MIMR-PHI Institute of Medical Research, Clayton, VIC, Australia; 4Mayo Clinic, Rochester, MN, United States; 5University of Edinburgh, Edinburgh, Lothian, United Kingdom; 6Peter MacCallum Cancer Centre, Australian Ovarian Cancer Study and CASCADE, East Melbourne, VIC, Australia; 7Royal Melbourne Hospital and Monash University, Melbourne, VIC, Australia; 8BC Cancer Agency and OVCARE Tissue Bank, Vancouver, BC, Canada; 9Walter and Eliza Hall Institute, Royal Melbourne and Royal Women’s Hospitals, Parkville, VIC, Australia
11:45 Genomic consequences of aberrant DNA repair stratify ovarian cancer histotypes
SY-01.06
Yikan Wang1; Ali Bashashati1; Michael Anglesio2; Dawn Cochrane1; Diljot Grewal2; Hugo Horlings1; Anthony Karnezis1; Anne-Marie Mes-Mason3; Aikou Okamoto4; Satoshi Yanagida4; Nozomu Yanaihara4; Misato Saito4; Blake Gilks2; Jessica McAlpine2; Samuel Aparicio1; David Huntsman2; Sohrab Shah2
1BC Cancer Agency, Vancouver, BC, Canada; 2University of British Columbia, Vancouver, BC, Canada; 3University of Montreal, Montreal, QC, Canada; 4The Jikei University School of Medicine, Minato, Tokyo, Japan

12:00 - 13:00  Lunch Break in Watermark (Dessert and coffee will be served at the poster session)

13:00 - 14:30  Poster Session I - Genetics, Genomics, Proteomics, Biomarkers, Pathology, Epidemiology & Prevention, Cell Culture and Animal Model Systems

Characterization of small nucleolar ARNS (snoRNAs) in low malignant potential and high grade serous ovarian cancer tissues by transcriptomics
P-01
Audrey Roy1; Fabien Dupuis-Sandoval1; Sonia Couture2; Ryan Nottingham3; Alan Lambowitz3; Sherif Abou-Elela2; Michelle Scott1
1Department of Biochemistry, Université de Sherbrooke, Sherbrooke, QC, Canada; 2Department of Microbiology, Université de Sherbrooke, Sherbrooke, QC, Canada; 3Institute for Cellular and Molecular Biology, University of Texas at Austin, Austin, TX, United States
Elucidating the role of GALNT3 mediated aberrant mucin O-glycosylation in the progression of epithelial ovarian cancer
P-03
Razan Sheta1,2Christina M. Woo3, Florence Roux-Dalvai4, Frédéric Fournier4, Sylvie Bourassa4, Arnaud Droit1,4, Carolyn R. Bertozzi3,5 and Dimcho Bachvarov1,2

1Department of Molecular Medicine, Laval University, Québec PQ, Canada
2Centre de recherche du CHU de Québec, L’Hôtel-Dieu de Québec, Québec PQ, Canada
3Department of Chemistry, Stanford University, Stanford, CA, USA
4Centre de recherche du CHU de Québec, CHUL, Québec PQ, Canada
5Howard Hughes Medical Institute, Stanford University, Stanford, CA USA
GREB1 is frequently expressed in the female reproductive tract and all ovarian cancer histotypes and promotes proliferation in ovarian cancer cell lines and mouse models
P-05
Kendra Hodgkinson1; Bojana Djordjevic2; Kenneth Garson3; Barbara Vanderhyden1
1Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada; 2Department of Pathology and Laboratory Medicine, The Ottawa Hospital, Ottawa, ON, Canada; 3Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada
A targeted next generation sequencing assay to characterize relevant cancer variants in solid tumor samples
P-07
Nick Khazanov
Thermo Fisher Scientific, Ann Arbor, MI, United States
The Prevent Ovarian Cancer Program (POCP): a new model for the identification and care of women at risk for ovarian cancer
P-11
Alicia Tone1; Jeanna McCuaig1; Carl Virtanen1; Sarah Ferguson1; Raymond Kim1; Gary Rodin1; Patricia Shaw2; Amit Oza1; Suzanne Kamel-Reid1; Tracy Stockley1; Marcus Bernardini1
1Princess Margaret Cancer Centre, Toronto, ON, Canada; 2University Health Network, Toronto, ON, Canada
Differential gene expression in fallopian tube epithelial cells associated with BRCA1 or BRCA2 mutation status and periovulatory follicular fluid exposure.
P-13
Julia Hollingsworth1; Carl Virtanen2; Angela Lau3; Alexandra Kollara3; Lisa Allen4; Terry Colgan1; Valerie Dube4; Barry Rosen5; K. Joan Murphy5; Ellen Greenblatt6; Tomer Feigenberg5; Alicia Tone5; Theodore Brown3
1Mount Sinai Hospital, Toronto, ON, Canada; 2PMH Genomics Centre, Toronto, ON, Canada; 3Lunenfeld Tanenbaum Research Institute, Toronto, ON, Canada; 4Women's College Hospital, Toronto, ON, Canada; 5Princess Margaret Cancer Centre, Toronto, ON, Canada; 6Mount Sinai Hospital, Toronto, ON, Canada
Regulation of ovarian surface epithelium stem cells by transforming growth factor beta 1 is mediated by Ptgs2 activation and Brca1 repression
P-15
Lauren Carter1; Olga Collins2; Lisa Gamwell1; David Cook1; Curtis McCloskey1; Holly Dempster1; Barbara Vanderhyden2
1University of Ottawa, Ottawa, ON, Canada; 2Ottawa Hospital Research Institute, Ottawa, ON, Canada
LKB1 is a central mediator of cell survival during stress metabolism in dormant ovarian cancer
P-17
Adrian Buensuceso; Yudith Ramos Valdes; Gabriel DiMattia; Trevor Shepherd
The University of Western Ontario, London, Ontario, Canada
Functional analysis of the cell adhesion molecule Nectin-4 in ovarian cancer tumor progression
P-19
Kristin Boylan; Petra Buchanan; Dip Shukla; Cody Bruggemeyer; Kelly Braumberger; Amy Skubitz
University of Minnesota, Minneapolis, MN, United States
Androgen receptor dependence for spontaneous juvenile-onset granulosa cell tumour initiation in a mouse model
P-21
Kerri Smith; Elizabeth Chia; Ann Dorward
Memorial University of Newfoundland, St. John's, NL, Canada
Mechanisms driving tumorigenesis and histotype differentiation of high-grade serous ovarian cancer in Stk11/Pten-deleted mouse ovarian surface epithelium
P-23
Julienne Brock1; Timothy DeKoninck2; Jose Teixeira3
1College of Natural Science, Department of Physiology, Michigan State University, Grand Rapids, MI, United States; 2College of Human Medicine, Michigan State University, East Lansing, MI, United States; 3College of Human Medicine, Department of Obstetrics, Gynecology and Reproductive Biology, Michigan S, Grand Rapids, MI, United States
Global analysis of whole exome sequencing data from BRCA1/BRCA2 mutation carrier French Canadian women with ovarian cancer
P-25
Wejdan Alenezi1; Suzanna L. Arcand2; Dunarel Badescu3; Timothee Revil3; Anne-Marie Mes-Masso4; Diane Provencher4; Ioannis Ragoussis3; Patricia N. Tonin5
1Department of Human Genetics, McGill University, Montreal, QC, Canada; 2Cancer Research Program, The Research Institute of McGill University Health Centre, Montreal, QC, Canada; 3McGill University and Génome Québec Innovation Centre; Department of Human Genetics, McGill University, Montreal, QC, Canada; 4Centre de recherche du Centre hospitalier de l'Université de Montréal et Institut du cancer de Montreal, Montreal, QC, Canada; 5Departments of Human Genetics and Medicine, McGill University; Cancer Research Program, The Research, Montreal, QC, Canada
Micro-dissected ovarian tumors on-chip and protein biomarkers to predict carboplatin response of epithelial ovarian cancer
P-27
Euridice Carmona1; Benjamin Péant1; Mélina Astolfi2; Abdul Lateef1; Jennifer Kendall-Dupont1; Liliane Meunier1; Diane Provencher1; Thomas Gervais2; Anne-Marie Mes-Masson1
1Institut du cancer de Montréal, CRCHUM, Montreal, QC, Canada; 2Institut de génie biomédical, École Polytechnique, Montreal, QC, Canada
Diagnostic markers for patients with ovarian granulosa cell tumors; comparative analysis of CA125, HE4, Inhibin B and AMH
P-29
Ulla-Maija Haltia1; Marianne Hallamaa2; Johanna Tapper1; Johanna Hynninen2; Henrik Alfthan3; Olli Ritvos4; Markku Heikinheimo5; Leila Unkila-Kallio1; Antti Perheentupa2; Anniina Färkkilä1
1University of Helsinki, Department of Obstetrics and Gynecology and Helsinki University Central Hospital, Helsinki, Finland, Finland; 2University of Turku, Department of Obstetrics and Gynecology and Turku University Hospital, Turku, Finland, Finland; 3University of Helsinki, HUSLAB and Helsinki University Central Hospital, Helsinki, Finland; 4University of Helsinki, Finland; 5University of Helsinki, Children´s Hospital and Helsinki University Central Hospital, Helsinki, Finland
Analysis of genetic abnormalities involved in the development of ovarian tumors
P-31
Hanna Engqvist1; Elisabeth Werner Rönnerman1; Toshima Parris1; Elin Söderberg1; Jana Biermann1; Karin Sundfeldt1; Aniko Kovacs2; Per Karlsson1; Khalil Helou1
1Clinical Sciences/University of Gothenburg, Gothenburg, Vastra Gotaland, Sweden; 2Clinical Pathology and Genetics/University of Gothenburg, Vastra Gotaland, Sweden
Assessment of Pan-Canadian platform for known/proposed ovarian cancer susceptibility genes
P-33
Suzanna L. Arcand1; Dunarel Badescu2; Timothée Revil2; Pierre Bérubé3; Ioannis Ragoussis2; Patricia N. Tonin4
1Cancer Research Program, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada; 2McGill University and Génome Québec Innovation Centre; Department of Human Genetics, McGill University, Montreal, QC, Canada; 3McGill University and Génome Québec Innovation Centre, Montreal, QC, Canada; 4Departments of Human Genetics and Medicine, McGill University; Cancer Research Program, The Research, Montreal, QC, Canada
Relationship between genotype and clinical phenotype in French Canadian BRCA1-2 mutated women with ovarian cancer (FC-BMOC)
P-35
Diane Provencher1; Olivier Charrette2; Gilles Bleau2; Zaki El Haffaf3; Kurosh Rahimi1; Serge Nolet3; Patricia Tonin4
1CHUM - Notre-Dame Hospital, Montreal, QC, Canada; 2Université de Montréal, Montreal, QC, Canada; 3CRCHUM, Montreal, QC, Canada; 4McGill University, Montreal, QC, Canada
17Beta-estradiol sensitizes ovarian surface epithelium to transformation by suppressing Dab2 expression
P-37
Nhung Vuong; Barbara Vanderhyden
University of Ottawa, Ottawa, ON, Canada
Therapeutic relevance of Ran GTPase in epithelial ovarian cancer
P-39
Zied Boudhraa; Guergana Tchakarska; Estelle Schmitt; Kossay Zaoui; Euridice Carmona; Anne-Marie Mes-Masson
CRCHUM, Montreal, QC, Canada
Interaction between the Notch and TGFbeta; signaling pathways in epithelial ovarian cancer cells
P-41
Jiesi Zhou; Abul Azad; Saket Jain; Xia Xu; HaiChuan Yu; Zhihua Xu; Roseline Godbout; YangXin Fu
University of Alberta, Edmonton, AB, Canada
Development of in vitro disease models to study inactivating mutations of SWI/SNF protein complexes in aggressive dedifferentiated gynecological carcinomas
P-43
Mackenzie Coatham1; Xiaodong Li1; Bo Meng1; Martin Kobel2; Cheng-Han Lee1; Lynne-Marie Postovit1
1University of Alberta, Edmonton, AB, Canada; 2University of Calgary, Calgary, AB, Canada
Ventricular Zone Expressed Pleckstrin Homology Domain Homolog 1 (VEPH1) modulation of androgen signaling in ovarian cancer cells
P-45
Premalatha Shathasivam; Alexandra Kollara; Theodore Brown
LTRI, Mount Sinai Hospital, Toronto, ON, Canada
Sphingosine-1-phosphate (S1P) promote ovarian cancer proliferation by disrupting Hippo signaling
P-47
Qianlan Fan
University of British Columbia, Vancouver, BC, Canada
The role of ADAM10 and ADAM17 in ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer
P-49
Petra Buchanan; Kristin Boylan; Bruce Walcheck; Amy Skubitz
UMN, Minneapolis, MN, United States
Mesothelial-tumor cell interactions for the formation of ovarian cancer multicellular spheroids
P-51
Clara Major Legault; Isabelle Matte; Claude Laplante; Perrine Garde-Granger; Paul Bessette; Alain Piché
Université de Sherbrooke, Sherbrooke, QC, Canada
The regulation of ovarian cancer cell dormancy by the DREAM complex
P-53
Piru Perampalam1; James MacDonald2; Yudith Ramos2; Gabe DiMattia2; Fred Dick2
1UWO/London Regional Cancer Program, London, ON, Canada; 2UWO/London Regional Cancer Program, London, ON, Canada
Investigation of solute carrier Slc25a53 as a candidate ovarian tumour suppressor gene
P-55
Emily Cruickshank; Elizabeth Chia; Ann Dorward
Memorial University of Newfoundland, St. John's, NL, Canada
Biology and tumorigenic capacity of self-assembled multicellular structures derived from serous ovarian cancer cells
P-57
Alicia A Goyeneche1; Juan M Valdez2; Rekha Srinivasan2; Zu-Hua Gao1; Carlos M Telleria1
1Department of Pathology, Faculty of Medicine, McGill University, Montreal, QC, Canada; 2Division of Basic Biomedical Sciences, Sanford School of Medicine of The University of South Dakota, Vermillion, SD, United States

14:30 - 17:00  Symposium II-Innovations in Experimental Model Systems
Moderators:
Theodore Brown, PhD, Lunenfeld-Tanenbaum Research Insitute and University of Toronto, Toronto, ON, Canada
Blaise Clarke, MD, University of Toronto, Toronto, ON, Canada


Coffee Station Available in Ballroom Foyer from 15:30-16:30

14:30 Staring down the tube at the origins of ovarian cancer: impact on model systems
SY-02.01
Ron Drapkin
Tenured Associate Professor; Director of Penn Ovarian Cancer Research Center; Director of Gynecology, Philadelphia, PA, United States
15:30 Gambling with biomarkers or going with the flow - patient derived models for personalized medicine
SY-02.02
Anne-Marie Mes-Masson
Institut du cancer de Montréal, Montreal, QC, Canada
16:00 Ovarian cancer spheroids as an experimental model system for interrogating tumour dormancy
SY-02.03
Trevor Shepherd
London Regional Cancer Program; Lawson Health Research Institute; Schulich School of Medicine & Dentistry, London, ON, Canada
16:30 Exploration SWI/SNF-PI3-kinase pathway crosstalk identifies new vulnerabilities in ARID1A-deficient ovarian tumors
SY-02.04
Jeanne Holladay; Ronald Chandler
Michigan State University, Grand Rapids, MI, United States
16:45 The active sodium-glucose symporter SGLT2 is protective against cancer death, primary tumor growth, and metastatic secondary disease in an orthotopic mouse model of epithelial ovarian cancer
SY-02.05
Lisa Kellenberger; Jim Petrik
University of Guelph, Guelph, ON, Canada

17:00 - 17:30  OCC Wine and Cheese Reception

 17:30 - 18:30  Special Performance by Jenny Allen "I got sick, then I got better"

0 comments :

Post a Comment

Your comments?